Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8.

View in: PubMed

subject areas

Age Factors
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
beta 2-Microglobulin
Cell Proliferation
Cyclophosphamide
Cytarabine
Dexamethasone
Doxorubicin
Epidemiologic Methods
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Mantle-Cell
Methotrexate
Middle Aged
Rituximab
Treatment Outcome
Vincristine

authors with profiles

HAGOP M KANTARJIAN
FREDRICK B HAGEMEISTER
MARIA A RODRIGUEZ
LUIS E FAYAD
LUHUA WANG
FELIPE SAMANIEGO